What is the main purpose of this 8-K filing for Boston Scientific?

This 8-K filing announces a material definitive agreement for Boston Scientific to merge with Guidant Corporation. It details the terms of the merger, the consideration to be paid to Guidant shareholders, and the conditions required for the transaction to close.

What will Guidant shareholders receive in the merger?

Guidant shareholders will receive a combination of $42.00 in cash and Boston Scientific common stock with a value of $38.00, based on a 20-day average closing price of BSX stock. The exact number of BSX shares is subject to a collar range, with fixed exchange ratios if BSX's average stock price falls below $22.62 or exceeds $28.86.

Are there any significant conditions that must be met for this merger to be completed?

Yes, the merger is subject to several key conditions, including approval from the shareholders of both Boston Scientific and Guidant, clearance under antitrust regulations like the Hart-Scott-Rodino Act and European Union merger control, and other customary closing conditions.

How does the transaction with Abbott Laboratories relate to the Guidant merger?

The transaction with Abbott Laboratories is a crucial component of the overall Guidant acquisition. Abbott will acquire specific Guidant businesses (vascular intervention and endovascular solutions) for $4.1 billion. This enables Boston Scientific to proceed with the merger by divesting those assets. Additionally, Abbott will provide financing to Boston Scientific through a loan and a stock purchase, supporting the merger's financial structure.

BSX 8-K: Material Agreements

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report announcing a significant material definitive agreement: a merger with Guidant Corporation. This transaction, outlined in an Agreement and Plan of Merger dated January 25, 2006, involves Boston Scientific's wholly-owned subsidiary, Galaxy Merger Sub, Inc., merging with Guidant. Upon completion, Guidant shareholders will receive a combination of cash and Boston Scientific common stock. The deal is subject to various closing conditions, including shareholder approvals from both companies and antitrust clearances. Furthermore, the filing details a related transaction with Abbott Laboratories, which will acquire Guidant's vascular intervention and endovascular solutions businesses for $4.1 billion, with potential additional payments. As part of this agreement, Abbott will also provide a loan to Boston Scientific and purchase a significant stake in Boston Scientific's common stock, indicating strategic support for the overall transaction. This series of agreements signals a major strategic move for Boston Scientific, aiming to expand its market presence through the acquisition of Guidant.

Key Highlights

1Boston Scientific Corporation entered into a Merger Agreement with Guidant Corporation on January 25, 2006.
2The merger will be effected through Boston Scientific's subsidiary, Galaxy Merger Sub, Inc., merging into Guidant.
3Guidant shareholders will receive $42.00 in cash and Boston Scientific stock valued at $38.00, subject to price fluctuations and a fixed exchange ratio if BSX's stock price falls below $22.62 or exceeds $28.86.
4The transaction is contingent upon shareholder approvals from both BSX and Guidant, as well as regulatory clearances, including HSR and EU merger control.
5A related agreement with Abbott Laboratories involves Abbott acquiring Guidant's vascular intervention and endovascular solutions businesses for $4.1 billion, plus potential milestone payments.
6As part of the Abbott deal, Abbott will provide Boston Scientific with a $900 million loan and purchase $1.4 billion of Boston Scientific common stock.
7Both parties have termination rights, with potential break-up fees of $800 million payable by either Boston Scientific or Guidant under specific circumstances.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (Jan 27, 2006)

Summary

Key Highlights

Frequently Asked Questions